NRx Pharmaceuticals, Inc.
NRXP
$3.37
-$0.10-2.88%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 72.99% | 29.56% | 75.93% | 16.56% | -35.40% |
| Depreciation & Amortization | -- | -- | 4,100.00% | 1,200.00% | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 103.81% | 55.22% | 53.47% | 44.28% | -47.09% |
| Operating Income | -74.29% | -26.71% | -26.42% | -36.27% | 47.09% |
| Income Before Tax | 6.03% | 74.06% | 103.97% | -262.91% | -122.63% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 6.03% | 74.06% | 103.97% | -262.91% | -122.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 6.03% | 74.06% | 103.97% | -262.91% | -122.63% |
| EBIT | -74.29% | -26.71% | -26.42% | -36.27% | 47.09% |
| EBITDA | -72.43% | -25.07% | -25.30% | -36.05% | 47.10% |
| EPS Basic | 55.24% | 86.84% | 101.67% | -79.11% | -30.57% |
| Normalized Basic EPS | 34.53% | 83.59% | 76.52% | 25.71% | 10.49% |
| EPS Diluted | 55.24% | 86.84% | 101.67% | -79.11% | -30.57% |
| Normalized Diluted EPS | 34.53% | 83.59% | 76.52% | 25.71% | 10.49% |
| Average Basic Shares Outstanding | 109.93% | 96.98% | 136.39% | 102.59% | 70.52% |
| Average Diluted Shares Outstanding | 109.93% | 96.98% | 136.39% | 102.59% | 70.52% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |